BMT CTN 0801: Chronic GVHD TreatmentMukta AroraMD MS
onic GVHD Treatment BMT CTN 0801: Chronic GVHD TreatmentBMT CTN 0801: Chronic GVHD TreatmentIris Gersten, MS
Results: Of 636 evaluable patients (84% of all BMT CTN 0702 participants), LC-only disease was noted in 18.9% (n=120). Pre-enrollment 24HRU testing at diagnosis was done in 28.9% of patients (n=184). IMWG responses were as follows: CR, 29.4% (n=187) traditional vs 29.7% (n=189...
Mark J. Levis, MD, PhD, discusses the takeaways from the phase 3 BMT CTN 1506/MORPHO trial which evaluated maintenance gilteritinib after allogeneic stem cell transplant in patients with FLT3-ITD–positive acute myeloid leukemia.Video Player is...
西罗莫司对比泼尼松作为标准风险急性移植物抗宿主病初始治疗的随机多中心临床研究:BMT CTN 1501试验 Joseph Pidala,1Mehdi Hamadani,2,3Peter Dawson,4Michael Martens,4Amin M. Alousi,5Madan Jagasia,6Yvonne A. Efebera,7Saurabh ...
Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated 来自 dx.doi.org 喜欢 0 阅读量: 1 摘要: Levis:Daiichi-Sankyo:Consultancy;Bristol Myers Squibb:Consultancy;Abbvie:Consultancy;Jazz:Consultancy;Astellas Global...
ClinicalTrials数据库提供临床试验MM CAR-T to Upgrade Response BMTCTN1902的登记号NCT05032820,试验分期Phase 2以及申办者Marcelo Pasquini, MD的信息,更过关于临床试验的其他信息查询就在戊戌数据美国临床试验数据库.
The Sickle Cell Unrelated Donor Transplant Trial (SCURT trial) of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) is a phase II study of the toxicity and efficacy of unrelated donor hematopoietic cell transplantation in children with severe sickle cell disease (SCD) using a ...
该试验评估了FLT3-ITD阳性急性髓细胞白血病(AML)患者接受异基因干细胞移植(ASCT)后的维持性吉替尼(Xospata)。 虽然该研究未能达到其无复发生存期(RFS)的主要终点,但接受吉瑞替尼治疗的患者在RFS方面取得了数值上但无统计学意义的改善(HR,0.679;95% CI,0.459-1.005;双面P = .0518)。
沈阳比亚迪海洋网(沈北新区店),沈阳比亚迪盛世新景汽车销售有限公司官方账号。沈阳比亚迪海洋网(沈北新区店)的抖音主页、视频、合集以及作品的粉丝量、点赞量。来抖音,记录美好生活!